Physician profile
Curt A Vogel
NPI 1609831932
$6,940.97
in general payments reported to CMS, 2019-2025
31 companies · $911 in 2025
The $911 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $453 · 2021: $1,657 · 2022: $965 · 2023: $487 · 2024: $860 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Education: $84.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.06 |
| Education | $84.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.77 | 2019-2025 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $789.68 | 2021-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $686.96 | 2019-2025 | Libtayo, Dupixent |
| Pfizer INC. | $683.04 | 2019-2025 | |
| Janssen Biotech, INC. | $532.65 | 2019-2025 | Tremfya |
| Genzyme Corporation | $390.94 | 2019-2025 | |
| Incyte Corporation | $373.14 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $332.28 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $297.05 | 2019-2025 | Anzupgo |
| Sun Pharmaceutical Industries INC. | $271.72 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $260.03 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $227.28 | 2020-2021 | |
| Amgen INC. | $205.21 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $150.12 | 2023-2025 | Zoryve |
| Regeneron Pharmaceuticals, INC. | $129.86 | 2024 | Libtayo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $85.57 | 2024-2025 | Aquacel Ag Surgical |
| Ucb, INC. | $75.91 | 2021 | |
| Galderma Laboratories, L.P. | $67.05 | 2019-2025 | Nemluvio |
| Dermira, INC. | $66.18 | 2019 | |
| Biofrontera INC. | $66.04 | 2019-2021 | |
| Smith+Nephew, INC. | $63.10 | 2024 | Stravix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.18 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.61 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $41.21 | 2024-2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $39.82 | 2020-2021 | |
| Almirall LLC | $38.93 | 2021 | |
| Krystal Biotech INC | $28.33 | 2023 | Vyjuvek |
| Strata Skin Sciences, INC. | $26.01 | 2025 | Xtrac |
| Celgene Corporation | $24.13 | 2019 | |
| Organon LLC | $13.35 | 2025 | Vtama |
| Tactile Systems Technology INC | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Vogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.